Analysts Expect SUMMIT THERAPEU/S (NASDAQ:SMMT) to Post -$0.23 Earnings Per Share

Wall Street brokerages expect that SUMMIT THERAPEU/S (NASDAQ:SMMT) will report earnings of ($0.23) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for SUMMIT THERAPEU/S’s earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.19). SUMMIT THERAPEU/S posted earnings of ($0.65) per share during the same quarter last year, which suggests a positive year over year growth rate of 64.6%. The company is expected to report its next earnings report on Tuesday, December 10th.

On average, analysts expect that SUMMIT THERAPEU/S will report full-year earnings of ($0.83) per share for the current fiscal year, with EPS estimates ranging from ($0.92) to ($0.76). For the next financial year, analysts anticipate that the company will report earnings of ($0.82) per share, with EPS estimates ranging from ($0.88) to ($0.74). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for SUMMIT THERAPEU/S.

SUMMIT THERAPEU/S (NASDAQ:SMMT) last released its quarterly earnings data on Friday, October 11th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.08. The business had revenue of $0.15 million during the quarter, compared to the consensus estimate of $0.43 million. SUMMIT THERAPEU/S had a negative return on equity of 61.73% and a negative net margin of 1,432.73%.

SMMT has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of SUMMIT THERAPEU/S from a “buy” rating to a “hold” rating in a research note on Wednesday, October 16th. TheStreet cut shares of SUMMIT THERAPEU/S from a “c-” rating to a “d-” rating in a report on Friday, October 11th. ValuEngine cut shares of SUMMIT THERAPEU/S from a “sell” rating to a “strong sell” rating in a report on Tuesday. Finally, HC Wainwright set a $2.00 target price on shares of SUMMIT THERAPEU/S and gave the stock a “buy” rating in a report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. SUMMIT THERAPEU/S currently has an average rating of “Hold” and an average price target of $1.88.

Shares of SUMMIT THERAPEU/S stock traded down $0.05 during trading on Friday, reaching $1.51. The company had a trading volume of 1 shares, compared to its average volume of 28,585. The company has a market cap of $50.08 million, a price-to-earnings ratio of 1.80 and a beta of 1.23. The firm’s fifty day moving average is $1.67 and its 200-day moving average is $1.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.47 and a current ratio of 3.47. SUMMIT THERAPEU/S has a fifty-two week low of $1.10 and a fifty-two week high of $2.46.

An institutional investor recently raised its position in SUMMIT THERAPEU/S stock. Bank of New York Mellon Corp raised its holdings in shares of SUMMIT THERAPEU/S (NASDAQ:SMMT) by 120.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 216,897 shares of the company’s stock after buying an additional 118,501 shares during the period. Bank of New York Mellon Corp owned about 1.57% of SUMMIT THERAPEU/S worth $274,000 as of its most recent SEC filing. 8.31% of the stock is currently owned by institutional investors.

SUMMIT THERAPEU/S Company Profile

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Recommended Story: Which market index is the best?

Get a free copy of the Zacks research report on SUMMIT THERAPEU/S (SMMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SUMMIT THERAPEU/S (NASDAQ:SMMT)

Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with MarketBeat.com's FREE daily email newsletter.